Probiodrug AG Reported on the Results of its Clinical Phase IIa Trial with the DPIV Inhibitor P93/01 in Type 2 Diabetes and its Patent Licensing Programs

Halle (Saale), Germany //
Probiodrug AG, a private biotech company headquartered in Halle, Germany, announced today its expectation to have favorable results to report on its first Phase IIa trial of its DP IV inhibitor, P93/01, in diabetics. The double-blind, placebo-controlled, cross-over trial, performed in Germany with 16 drug-naïve diabetes patients, showed a statistically significant (p<0.05) reduction of meal-induced glucose excursions. Furthermore, the data reveal that this reduction is more pronounced in patients with higher values of HbA1c. Neither treatment-related adverse events nor hypoglycemia occurred. The company plans, after having performed further studies in healthy volunteers, to initiate a 3 months Phase II clinical trial in the first half of 2004. For this trial 100 diabetes patients will be enrolled. An IND is expected to be filed in early 2004. As confirmed by recent trade conference announcements from a number of major pharmaceutical and biotech companies describing their pre-clinical and clinical progress, treatment of diabetes by therapeutic delivery of DP IV inhibitors represents a dramatically promising and exciting new development in patient care. As a pioneer in this field with an extensive and broad patent portfolio, Probiodrug is proud to assist in advancing this technology and making available non-exclusive licenses to certain of its fundamental patents. Further details concerning its patented technologies, its licensing program, as well as foreseeable changes affecting financial terms and availability may be obtained by visiting Probiodrug’s web-site at www.probiodrug.de.

About Probiodrug AG

Probiodrug is a drug discovery company with a focus on enzyme targets including DP IV. Probiodrug endeavors to identify new orally active compounds for selectively modifying enzymatic activity in order to derive therapeutic effect. Its most advanced program is currently focused on treating Type 2 Diabetes using its lead candidate, P93/01, an orally active inhibitor of DP IV. Probiodrug has actively pursued patent protection for its lead and back-up compounds as well as for fundamental treatment technologies addressing diabetes, obesity, blood pressure, cancer and other diseases.

Probiodrug AG
Dr Konrad Glund
Weinbergweg 22
D-06120 Halle (Saale)
Germany
Tel.: +49 345 55599-00
Fax: +49 345 55599-01
Mail: konrad.glund@probiodrug.de